Conditions: Lupus Erythematosus, Systemic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 30
Healthy volunteers: no

Brief summary:
The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.

Detailed description:

Arms:
arm 1: Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes. arm 2: Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.

Interventions: intervention 1: Ala-Cpn10 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: